Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature

Significant efforts have been made to investigate the molecular pathways involved in thymic carcinogenesis. However, genetic findings have still not impacted clinical practice. The aim of this exploratory trial was to evaluate the immunoscore and molecular profile of a series of thymic carcinomas (TCs), correlating this data with clinical outcome.

[1]  M. Satouchi,et al.  Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a multicenter phase II (REMORA) trial , 2019, Annals of Oncology.

[2]  J. Ahn,et al.  Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[4]  S. Park,et al.  Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. , 2018 .

[5]  G. Giaccone,et al.  Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. , 2018 .

[6]  G. Giaccone,et al.  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. , 2018, The Lancet. Oncology.

[7]  Benjamin J. Raphael,et al.  The Integrated Genomic Landscape of Thymic Epithelial Tumors. , 2018, Cancer cell.

[8]  M. Aubry,et al.  Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  B. Moser,et al.  Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets , 2016, Pathology & Oncology Research.

[10]  E. Boerwinkle,et al.  dbNSFP v3.0: A One‐Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice‐Site SNVs , 2016, Human mutation.

[11]  M. Scorsetti,et al.  Thymoma and thymic carcinomas. , 2016, Critical reviews in oncology/hematology.

[12]  Jarret Glasscock,et al.  A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas , 2016, British Journal of Cancer.

[13]  Y. Ohe,et al.  Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. , 2015, Lung cancer.

[14]  P. Meltzer,et al.  Mutations of epigenetic regulatory genes are common in thymic carcinomas , 2014, Scientific Reports.

[15]  Jaime Rodriguez-Canales,et al.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors , 2014, Nature Genetics.

[16]  X. Liu,et al.  Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. , 2014, Genetics and molecular research : GMR.

[17]  S. Badve,et al.  A Gene Signature to Determine Metastatic Behavior in Thymomas , 2013, PloS one.

[18]  J. Galon,et al.  From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.

[19]  Lang Li,et al.  Molecular Analysis of Thymoma , 2012, PloS one.

[20]  P. Meltzer,et al.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors , 2012, Cell Death and Disease.

[21]  J. Wesche,et al.  Roles of Fibroblast Growth Factor Receptors in Carcinogenesis , 2010, Molecular Cancer Research.

[22]  Jana Marie Schwarz,et al.  MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.

[23]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[24]  N. Girard,et al.  Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas , 2009, Clinical Cancer Research.

[25]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[26]  I. Wistuba,et al.  Molecular pathology of thymic epithelial neoplasms. , 2008, Hematology/oncology clinics of North America.

[27]  R. Pfeiffer,et al.  Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.

[28]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[29]  Peter G. Korning,et al.  Splice Site Prediction in Arabidopsis Thaliana Pre-mRNA by Combining Local and Global Sequence Information , 1996 .

[30]  S. Suster,et al.  Thymic carcinoma. A clinicopathologic study of 60 cases , 1991, Cancer.

[31]  A. Thackray,et al.  Tumours of the thymus , 1967, Thorax.

[32]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[33]  Justin C. Fay,et al.  Identification of deleterious mutations within three human genomes. , 2009, Genome research.

[34]  Mark Culp,et al.  ada: An R Package for Stochastic Boosting , 2006 .